- |||||||||| 5-Hydroxytriptolide / Shanghai Pharma
A randomized controlled trial of (5R)-5-hydroxytriptolide in HIV INRs receiving ART (Poster Exhibition area) - May 5, 2023 - Abstract #IASHIV2023IAS_HIV_206; Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences, Shanghai Pharmaceuticals Holding Co., Ltd., and the National key technologies R&D program for the 13th five-year plan. Embargoes on oral abstracts and posters lift on Monday, 24 July 2023, at 09:00 Australian Eastern Standard Time (AEST).
- |||||||||| 5-Hydroxytriptolide / Shanghai Pharma
Trial completion, Trial completion date, Trial primary completion date: Safety and Efficacy of T8 on Treating Chronic Abnormal Immune Activation in AIDS Patients (clinicaltrials.gov) - Jul 26, 2022 P2, N=151, Completed, Embargoes on oral abstracts and posters lift on Monday, 24 July 2023, at 09:00 Australian Eastern Standard Time (AEST). Active, not recruiting --> Completed | Trial completion date: Mar 2022 --> Jul 2022 | Trial primary completion date: Sep 2021 --> Jul 2022
|